We can not yet know what reason is behind their joint downregulation, but another interesting common denominator is that 12 out of 13 genes share a regulatory motif for NF-kappaB (according to TRANSFAC, V$NFKB_Q6_01). A putative role for NF-kappaB in prostate cancer has been reported based on the observation of the centrality of NFKB on two up-and downregulated networks compairing prostate tumors and healthy tissue [546] and in a larger study by McDonnel et al. [547] (255 core prostate cancer tissue microarrays from 47 prostatectomy specimens). Several other researchers are currently investigating different roles of the NFKB family in prostate cancer [548, 549, 550, 551, 552, 553, 554, 555] and it could be a promising target for intervention [555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571 ]. If we include other genes following the ranking order, the first 38 genes in the ranking include 33 that have the regulatory motif V$NFKB_Q6_01 (GATHER reports for this list a p-value of 0.0006). Even when we double the list to the probes that correspond to the first 76 different genes recognized by GATHER, 58 of them have the regulatory motif V$NFKB_Q6_01, with p-value = 0.003 (ATP6AP2, BCAT1, BTG2 [572, 573, 574, 575, 576, 577, 578] , C14orf123, C18orf45, CCL2, CD302, CD40 (already discussed), CD59 (already discussed), CHI3L1, COL16A1, COMMD6, CRABP2, CSRP1, CTBP2, CTGF (Connective tissue growth factor, [579, 580, 581, 582] ), DES, DMN, DNAJB1, EGF, EMP1, FHL2 [583, 584, 585, 586, 587, 588] , GRIPAP1, GSTM1 [589, 590] , HBEGF, IL4R, ITGA3, ITGA7, JUNB [591, 592] , KIAA0152, KIAA1191, KIAA1324, KLF6, LAMB2, LMNA (already discussed), NFATC1, NFKB2, NUDC [593] , P4HB, PDK2, PIM1, PISD, PXN, RAP1B, RNF40, SARA1, SEC61A1, SGTA [594] , SLC12A2, SRD5A2, STAT6 [595, 596] , TACSTD2, TBX1, TMED3, VPS39, WDFY3, XBP1 [544] , ZAK). This result indicates that our results support the importance of NFkappa-B and the huge amount of research effort to understand the role of the NFkappa-B activity and its potential as a target for intervention in prostate cancer (File S4).